Liposomal drug for the treatment of leishmaniasis in dogs

The treatment of infectious diseases, such as leishmaniosis, can lead to toxicity. By encapsulating drugs in liposomes, we aim to achieve targeted delivery, reducing dosage and minimizing toxicity. In this project, I will lead the efforts to set up the protocols and coordinate the project to be able to offer liposomal treatments to dogs with leishmaniosis. First, liposomes of different lipid compositions will be prepared with anti-leishmania drugs and tested for quality control and stability. Once good quality liposomes have been successfully prepared, they will be tested on leishmania-infected canine macrophages in vitro to observe toxicity, efficacy, and uptake. The  best formulation will be prepared in a GMP setting, and additional quality control tests will be performed to ensure stability, reproducibility and sterility of the final product. The liposomes can then be offered to patients, and the efficacy of the product will be tested by observing clinical parameters.

Contact 
Chloé Catelain